Clinical trial
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to…
NCT00338650 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00338650 |
|---|---|
| Title | Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE) |
| Official title | A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | adalimumab |
| Enrollment | 1,000 |
| Start date | Jun 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Jun 20, 2006 |
| Last update posted | Nov 29, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: